Clinical Trials Browser

Neoplasms × Paclitaxel × Endocrine × Clear all

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1/2 Terminated

19 enrolled 13 charts

EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic